Effect of mesenchymal stem cells on skin graft to flap prefabrication: an experimental study.
Uysal CA., Ogawa R., Lu F., Hyakusoku H., Mizuno H.
Animal Study with a reported sample of 18, published in Ann Plast Surg (2010) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Ann Plast Surg (2010)
- Country
- United States
- Reported sample size
- 18
- Source database
- PubMed
- PMID
- 20585233
- DOI
- 10.1097/SAP.0b013e3181c1ff14
- Citations
- 20
Abstract (original English)
Angiogenetic potential has been reported for bone marrow-derived stem cells (BSCs) and adipose-derived stem cells (ASCs). The superficial femoral artery, vein, and fascia were used as a vascular crane for prefabrication model of skin graft to flap. BSCs or ASCs were injected before the adaptation of the graft to the vascular crane depending on the group. The prefabricated grafts were then transferred to inguinal region in every 7 days to observe the viability. In experiment part I (n = 18), the critical time for the prefabrication was found to be 1 week. In experiment part II (n = 12), the control and experiment assays were performed on the same animal to support the data of the experiment part I. The viability of flaps was evaluated. The vascular density was higher in BSC, and ASC groups. The Vascular Endothelial Growth Factor immunohistochemical staining was quantified. Furthermore, mesenchymal stem cells could be helpful in any prefabrication procedure in which neovascularization is indispensable.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.